###begin article-title 0
###xml 82 90 <span type="species:ncbi:9606">Patients</span>
###xml 115 126 <span type="species:ncbi:11103">Hepatitis C</span>
Th1 Disabled Function in Response to TLR4 Stimulation of Monocyte-Derived DC from Patients Chronically-Infected by Hepatitis C Virus
###end article-title 0
###begin p 1
Conceived and designed the experiments: VL LP SA PA. Performed the experiments: LP SA OD BV SD AG. Analyzed the data: VL LP SA PA OD. Wrote the paper: VL LP SA PA OD.
###end p 1
###begin p 2
###xml 70 71 70 71 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
Current address: Service de Recherches en Hemato-Immunologie-CEA-DSV-I2BM, Hopital Saint Louis, Paris, France
###end p 2
###begin title 3
Background
###end title 3
###begin p 4
###xml 97 108 <span type="species:ncbi:11103">hepatitis C</span>
Lack of protective antibodies and inefficient cytotoxic responses are characteristics of chronic hepatitis C infection. A defect in dendritic cell (DC) function has thus been suspected, but this remains a controversial issue.
###end p 4
###begin title 5
Methods and Findings
###end title 5
###begin p 6
###xml 71 79 <span type="species:ncbi:9606">patients</span>
###xml 203 211 <span type="species:ncbi:9606">patients</span>
###xml 369 372 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 642 645 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 646 654 <span type="species:ncbi:9606">patients</span>
###xml 875 878 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 879 887 <span type="species:ncbi:9606">patients</span>
###xml 928 931 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Here we show that monocyte-derived DC (MoDC) from chronically-infected patients can mature in response to TLR1/2, TLR2/6 or TLR3 ligands. In contrast, when stimulated with the TLR4 ligand LPS, MoDC from patients show a profound defect in inducing IFNgamma secretion by allogeneic T cells. This defect is not due to defective phenotypic maturation or to the presence of HCV-RNA in DC or monocytes but is correlated to reduced IL-12 secretion by DC. Restoration of DC ability to stimulate IFNgamma secretion can be obtained by blocking MEK activation in DC, indicating that MEK/ERK pathway is involved in the Th1 defect of MoDC. Monocytes from HCV patients present increased spontaneous secretion of cytokines and chemokines, especially MIP-1beta. Addition of MIP-1beta on healthy monocytes during differentiation results in DC that have Th1 defect characteristic of MoDC from HCV patients, suggesting that MIP-1beta secretion by HCV monocytes participates in the Th1 defect of DC.
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
###xml 38 41 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 42 50 <span type="species:ncbi:9606">patients</span>
Our data indicate that monocytes from HCV patients are activated in vivo. This interferes with their differentiation into DC, leading to deficient TLR4 signaling in these cells that are enable to induce a Th1 response. This specific defect is linked to the activation of the MEK/ERK pathway.
###end p 8
###begin title 9
Introduction
###end title 9
###begin p 10
###xml 120 123 120 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002260-Choo1">[1]</xref>
###xml 125 128 125 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002260-Miller1">[2]</xref>
###xml 387 390 387 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002260-Hoofnagle1">[3]</xref>
###xml 0 17 <span type="species:ncbi:11103">Hepatitis C virus</span>
###xml 19 22 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 130 133 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 196 202 <span type="species:ncbi:9606">people</span>
###xml 416 424 <span type="species:ncbi:9606">patients</span>
###xml 426 429 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Hepatitis C virus (HCV) is a single-stranded RNA virus classified in the Flaviviridae virus family by sequence homology [1], [2]. HCV infection is a major public health problem since 200 millions people are infected worldwide. The infection is characterized by a high rate of progression to chronicity which often leads to hepatic diseases such as cirrhosis and hepatocellular carcinoma [3]. In chronically infected patients, HCV often resists to clearance even after repeated antiviral treatments. Thus, the virus may have evolved strategies to escape the immune surveillance.
###end p 10
###begin p 11
###xml 141 144 141 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002260-AuffermannGretzinger1">[4]</xref>
###xml 145 149 145 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002260-Tsubouchi2">[11]</xref>
###xml 293 297 293 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002260-Longman1">[12]</xref>
###xml 298 302 298 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002260-Piccioli1">[14]</xref>
###xml 657 661 657 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002260-DellaBella1">[15]</xref>
###xml 791 795 791 795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002260-RodrigueGervais1">[16]</xref>
###xml 66 69 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 91 99 <span type="species:ncbi:9606">patients</span>
###xml 239 247 <span type="species:ncbi:9606">patients</span>
###xml 314 322 <span type="species:ncbi:9606">patients</span>
###xml 585 593 <span type="species:ncbi:9606">patients</span>
Several groups have reported that monocyte-derived DC (MoDC) from HCV chronically-infected patients have impaired allostimulatory capacities [4]-[11], however this was challenged by other groups showing that MoDC from chronically-infected patients could phenotypically and functionally mature [12]-[14]. Since the patients appear immunologically competent, major dysfunction of dendritic cells (DC) is not expected, rather a discrete DC function could be targeted by the virus without affecting global immunity. Recent studies reported that peripheral blood DC of chronically infected patients express less IL-12 than control cells from healthy individuals [15] and a small population of circulating myeloid DC displayed an impaired response to specific toll-like receptor (TLR) stimulation [16]. These transmembrane receptors expressed by cells of innate immunity are involved in the detection of microbes and activation of signaling pathways inducing the innate immune response.
###end p 11
###begin p 12
###xml 544 548 544 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002260-Li1">[17]</xref>
###xml 711 715 711 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002260-Bieback1">[18]</xref>
###xml 716 720 716 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002260-Sato1">[20]</xref>
###xml 929 933 929 933 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002260-KurtJones1">[21]</xref>
###xml 995 999 995 999 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002260-Rassa1">[22]</xref>
###xml 1046 1050 1046 1050 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002260-Haynes1">[23]</xref>
###xml 1163 1167 1163 1167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002260-Jude1">[24]</xref>
###xml 1338 1342 1338 1342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002260-Abe1">[25]</xref>
###xml 411 414 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 658 679 <span type="species:ncbi:10359">human cytomegalovirus</span>
###xml 683 710 <span type="species:ncbi:10298">herpes simplex virus type 1</span>
###xml 895 922 <span type="species:ncbi:12814">respiratory syncytial virus</span>
###xml 924 927 <span type="species:ncbi:12814?0.7497633322814768">RSV</span>
###xml 962 987 <span type="species:ncbi:11757">mouse mammary tumor virus</span>
###xml 989 993 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 1032 1035 <span type="species:ncbi:12814?0.7497633322814768">RSV</span>
###xml 1059 1063 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 1169 1172 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
There is increasing evidence that viruses can interact with TLR signaling. Viral components can either bind to TLR and activate their signaling pathway or block TLR function by interfering with intracellular intermediates. TLR3 activation can be triggered by polyriboinosinic-polyribocytidylic acid (poly I:C), a synthetic analog of double-stranded RNA (dsRNA) generated during viral replication. Moreover, the HCV serine protease NS3/4A can specifically degrade the adaptor protein TRIF resulting in inhibition of TLR3 signaling in HeLa cells [17]. TLR2 is also involved in the detection of viral components such as measles hemagglutinin or viruses such as human cytomegalovirus or herpes simplex virus type 1 [18]-[20]. Although TLR4 is well-known for its capacity to detect bacterial lipopolysaccharide (LPS), this receptor can also recognize viral components such as the fusion protein from respiratory syncytial virus (RSV) [21] and the envelope protein of mouse mammary tumor virus (MMTV) [22]. TLR4 is important for clearing RSV infection [23] whereas MMTV maintenance depends on TLR4 stimulation by the virus that induces immunoregulatory IL-10 secretion [24]. HCV non structural proteins such as NS5A can interact with MyD88, inhibiting TLR signaling and reducing cytokine production resulting from TLR activation in macrophages [25].
###end p 12
###begin p 13
###xml 192 200 <span type="species:ncbi:9606">patients</span>
###xml 225 228 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 413 421 <span type="species:ncbi:9606">patients</span>
We examined the type of T cell response elicited by myeloid DC derived from blood monocytes after stimulation with different TLR ligands. Here we show that DC differentiated from monocytes of patients chronically infected by HCV present an altered TLR4-induced maturation resulting in a deficient Th1 function that can be restored by inhibition of the MEK-ERK signaling pathway. The monocytes isolated from these patients have an increased level of activation and secrete higher amounts of cytokines and chemokines especially MIP-1 alpha and beta, that can interfere with DC functional maturation.
###end p 13
###begin title 14
Materials and Methods
###end title 14
###begin title 15
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 15
###begin p 16
###xml 166 173 <span type="species:ncbi:9606">patient</span>
###xml 381 389 <span type="species:ncbi:9606">patients</span>
Blood samples were obtained from volunteers attending the Liver Unit at Necker Hospital (Paris, France). Blood was collected with the written informed consent of the patient during a therapeutical bleeding prescribed by Pr. S. Pol (Service d'hepatologie, Hopital Cochin, Paris). Clinical protocols conformed to ethical guidelines of the authors' institutions. Chronically-infected patients have not been given antiviral therapy for more than six months. Viruses were of genotypes 1a, 1b, 3 and 4a.
###end p 16
###begin title 17
Monocyte purification and stimulation
###end title 17
###begin p 18
###xml 4 5 4 5 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 130 134 130 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002260-PerrinCocon1">[26]</xref>
###xml 761 762 761 762 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 160 165 <span type="species:ncbi:9606">human</span>
###xml 886 893 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
CD14+ monocytes were purified from peripheral blood of healthy or chronically-infected individuals mainly as previously described [26]. PBMC were isolated from human peripheral blood by standard density gradient centrifugation on Ficoll-Hypaque (GE healthcare, Uppsala, Sweden), then mononuclear cells were separated from PBL by centrifugation on a 50 % Percoll solution (GE healthcare). Monocytes were purified by immunomagnetic depletion (Dynal, Oslo, Norway), using a cocktail of mAbs anti-CD19 (4G7 hybridoma), anti-CD3 (OKT3, American Type Culture Collection, Rockville, MD, USA), anti-CD56 (NKH1, Beckman Coulter, Fullerton, CA, USA) and anti-CD16 (Beckman Coulter). Recovered monocytes were more than 90 % pure as assessed by CD14 labeling. Monocytes (106 cells/ml) could be stimulated for 24h in complete RPMI 1640 medium supplemented with 10% FCS, with either 1 microg/ml LPS (E. coli 055:B8, Sigma-Aldrich), 10 microg/ml poly I:C (pIC; GE healthcare), 10 microg/ml peptidoglycan (PGN; S. Aureus, Sigma-Aldrich) or 10 microg/ml Pam3CSK4 (Pam; Axxora, San Diego, CA). Cells were pelleted and supernatants harvested.
###end p 18
###begin title 19
###xml 0 3 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
HCV-RNA quantification
###end title 19
###begin p 20
###xml 25 26 25 26 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 299 303 289 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002260-Andre1">[27]</xref>
###xml 305 309 295 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002260-KomurianPradel1">[28]</xref>
###xml 438 442 424 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002260-Besnard1">[29]</xref>
###xml 159 162 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 223 226 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
RNA was extracted from 106 monocytes or PBL, using RNeasy mini kit (Qiagen, Courtaboeuf, France). RNA was eluted in 40 microl water and stored at -80degreesC. HCV-RNA quantification was performed by real-time PCR of the 5' HCV non-coding region as described previously, but with minor modifications [27], [28]. Briefly, RNA (4 microl) was reverse-transcribed with a Thermoscript reverse transcriptase kit (Gibco-BRL) with the RC21 primer [29]. Real-time PCR was carried out with 2 microl cDNA and the RC1 and RC21 primers by using an LC FastStart DNA Master SYBR Green I kit and a LightCycler apparatus (Roche Diagnostics).
###end p 20
###begin title 21
DC differentiation and maturation
###end title 21
###begin p 22
###xml 22 23 22 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 134 139 <span type="species:ncbi:9606">human</span>
###xml 163 168 <span type="species:ncbi:9606">human</span>
Purified monocytes (106 cells/ml) were differentiated to immature DC in complete RPMI 1640 medium supplemented with 10% FCS, 50 ng/ml human rGM-CSF and 62.5 ng/ml human rIL-4 (from AbCys, Paris, France) during 6 days. Maturation was induced at day 5 with LPS (1 microg/ml), PGN (10 microg/ml), Pam (10 microg/ml) or pIC (10 microg/ml). When indicated, cells were pre-incubated with 40 microM MEK inhibitor (PD98059; Biomol, Plymouth Meeting, PA, USA) at day 4, or with 200 ng/ml MIP-1beta or 20 ng/ml MIP-1alpha (R&D systems, Minneapolis, MN, USA) at day 0. All cells and culture supernatants were collected at day 6.
###end p 22
###begin title 23
Phenotype
###end title 23
###begin p 24
Phenotype was analyzed by flow cytometry on a FACSCalibur (BD Biosciences, Franklin Lakes, NJ) using FITC-conjugated anti-CD14, -HLA-DR, -CD80, -CD54 and PE-conjugated anti-CD1a, -CD86, -CD83 and -CD40 (all from Beckman Coulter).
###end p 24
###begin title 25
Cytokine assay
###end title 25
###begin p 26
Culture supernatants were stored at -80degreesC. Cytokine concentrations were determined using sandwich ELISA specific for IL12p40 (Biosource, Camarillo, CA, USA), IL-6, TNFalpha, IL-10 and IL-13 (Endogen, Woburn, MA, USA) or using Cytometric Bead Array (CBA) inflammation kit or CBA flex (BD biosciences) for IFNgamma, IL-5, IP-10, MIP-1alpha, and MIP-1beta.
###end p 26
###begin title 27
Mixed Lymphocyte Reaction (MLR)
###end title 27
###begin p 28
###xml 14 15 14 15 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 82 86 82 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002260-PerrinCocon1">[26]</xref>
###xml 215 216 215 216 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
Allogeneic CD3+ T cells were purified from non-infected blood donors as described [26] and primary MLR were conducted in 96-well flat-bottom culture plates. DC recovered at day 6 were washed and cocultured with 2x105 allogeneic T cells at DC/T cell ratios ranging from 1/10 to 1/40. Culture supernatants were harvested after 5 d of coculture for IL-5, IL-13 and IFNgamma assay.
###end p 28
###begin title 29
Results
###end title 29
###begin title 30
###xml 36 39 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 40 48 <span type="species:ncbi:9606">patients</span>
Deficient Th1 function in MoDC from HCV patients upon LPS stimulation
###end title 30
###begin p 31
###xml 683 692 679 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002260-g001">figure 1A</xref>
###xml 1393 1402 1385 1394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002260-g001">figure 1A</xref>
###xml 47 55 <span type="species:ncbi:9606">patients</span>
###xml 508 516 <span type="species:ncbi:9606">patients</span>
###xml 889 892 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1136 1139 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1214 1217 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1227 1235 <span type="species:ncbi:9606">patients</span>
###xml 1415 1418 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1518 1521 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
The capacity of MoDC from chronically-infected patients to stimulate allogeneic T cells was examined by MLR experiments and compared to MoDC from healthy blood donors. Allogeneic T cells from healthy donors were used to assess MoDC ability to induce a Th1 or Th2 oriented response, upon activation by different TLR ligands. LPS was used as a prototype of TLR4 ligand, pIC for TLR3 stimulation, and PGN or Pam as ligands of the heterodimers TLR2/TLR6 or TLR2/TLR1 respectively. MoDC from chronically-infected patients stimulated with the TLR4 ligand LPS showed a strongly decreased ability to induce IFNgamma secretion by allogeneic T cells compared to MoDC from healthy individuals (figure 1A). These LPS-treated MoDC were only slightly more efficient than immature MoDC with a mean stimulation index of 1.6 compared to 24.3 for MoDC from healthy donors. This difference between MoDC from HCV and healthy individuals was statistically highly significant (p<0.01) using the non parametric Mann-Whitney rank test. No significant increase in Th2 cytokines such as IL-5 and IL-13 could be detected in coculture supernatants of T cells with HCV-MoDC compared with healthy MoDC (data not shown). Maturation of MoDC from HCV-infected patients stimulated by TLR2/6, TLR2/1 or TLR3 ligands yielded cells able to stimulate IFNgamma production by T cells as efficiently as MoDC from healthy individuals (figure 1A). Therefore HCV infection is associated with a selective Th1 defect of MoDC in the TLR4 pathway. To understand how HCV infection interferes with TLR4-induced maturation, we analyzed the phenotype and the cytokine secretion of mature cells.
###end p 31
###begin title 32
###xml 36 39 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 49 57 <span type="species:ncbi:9606">patients</span>
Comparison of MoDC from chronically HCV infected patients and healthy individuals upon TLR ligands stimulation.
###end title 32
###begin p 33
###xml 45 48 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 58 66 <span type="species:ncbi:9606">patients</span>
###xml 585 588 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 745 748 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 749 757 <span type="species:ncbi:9606">patients</span>
###xml 1022 1025 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1026 1033 <span type="species:ncbi:9606">patient</span>
###xml 1202 1205 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1206 1214 <span type="species:ncbi:9606">patients</span>
###xml 1279 1282 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1283 1291 <span type="species:ncbi:9606">patients</span>
MoDC from healthy individuals or chronically HCV infected patients were treated at day 5 with LPS, PGN, Pam or pIC for 24h. Control immature DC were obtained at day 6 without any treatment. (A) DC harvested at day 6 were cocultured for 5 days with allogeneic T cells at a ratio of 1/10 DC/T cell in triplicates. IFNgamma was assayed in coculture supernatants using CBA Flex kit. Stimulation index was determined as the ratio between stimulated DC and control iDC of the mean IFNgamma secretion for the triplicate. The Mann-Whitney U test was used to generate p value for comparison of HCV (n = 11) versus healthy (m = 17) individuals. The mean stimulation index for both groups is indicated on the graph and median values for healthy donors and HCV patients were respectively 1.1 and 6.2 with LPS-stimulated DC, 7.2 and 6.0 with PGN-stimulated DC, 8.1 and 7.9 with PAM-stimulated DC and 1.4 and 1.9 with pIC-stimulated DC. (B, C) Phenotypic analysis were performed on DC harvested at day 6 from an healthy donor (B) or an HCV patient (C). Representative results of one experiment out of eleven. (D, E) Cytokine secretions in DC supernatants harvested at day 6. Mean secretion+/-SD for eleven different HCV patients and 10 to 18 healthy donors. * The mean secretion of Mo-DC from HCV patients is lower than that of MoDC from healthy individuals with p<0.01 in a Student's test.
###end p 33
###begin p 34
###xml 121 133 121 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002260-g001">figure 1B, C</xref>
###xml 571 572 571 572 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 606 615 606 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002260.s001">figure S1</xref>
###xml 171 174 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 196 204 <span type="species:ncbi:9606">patients</span>
###xml 467 470 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 471 479 <span type="species:ncbi:9606">patients</span>
###xml 568 571 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 683 686 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 687 695 <span type="species:ncbi:9606">patients</span>
The expression of characteristic markers of DC maturation was upregulated on MoDC in response to TLR ligand stimulation (figure 1B, C). Without any stimulation, MoDC from HCV chronically-infected patients had the characteristics of immature DC. In response to TLR ligands, DC maturation resulted in enhanced expression of costimulation molecules (CD80, CD86, CD40), MHC class II and adhesion molecules (CD54) with similar efficiencies whether cells were derived from HCV patients or healthy donors. Differences in HLA-DR and CD86 expression levels between healthy and HCV+ individuals are donor-dependent (figure S1). Therefore the deficient Th1 function of LPS stimulated MoDC from HCV patients could not be explained by altered expression of these surface markers of DC.
###end p 34
###begin p 35
###xml 418 430 414 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002260-g001">figure 1D, E</xref>
###xml 775 783 771 779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002260-g002">figure 2</xref>
###xml 761 764 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 765 773 <span type="species:ncbi:9606">patients</span>
The cytokine secretion profile of mature DC participates in the orientation of the T cell response. Therefore we quantified the cytokines secreted in the supernatant of DC culture after 24 h maturation induced by the different TLR ligands. Pam or pIC-stimulated DC secreted low amounts of IL-6, TNFalpha, IL-10 and IL-12 whereas LPS or PGN-activated DC showed strong secretions of cytokines especially IL-6 and IL-12 (figure 1D, E). A significant difference could be observed for IL-12 secretion. Upon LPS stimulation, MoDC from chronically-infected individuals secreted lower amounts of IL-12 than MoDC from healthy individuals (p<0.01). Thus Th1 disabled function following TLR4 stimulation appeared to be correlated to low IL-12 secretion by DC derived from HCV patients (figure 2). IFNgamma secretion induced by LPS-stimulated MoDC from healthy donors was not correlated to the amount of secreted IL-12, indicating that in normal MoDC, IL-12 is not a limiting factor of the induction of the Th1 response.
###end p 35
###begin title 36
###xml 39 42 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 64 72 <span type="species:ncbi:9606">patients</span>
Decreased IL-12 secretion by MoDC from HCV-chronically infected patients is correlated to Th1 deficient function.
###end title 36
###begin p 37
###xml 429 430 421 422 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 10 13 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 35 43 <span type="species:ncbi:9606">patients</span>
MoDC from HCV chronically infected patients were treated at day 5 with LPS and harvested at day 6. IL-12p40 was quantified in the supernatants and DC were cocultured for 5 days with allogeneic T cells at a ratio of 1/10 DC/T cell. IFNgamma was measured by CBA in supernatants of cocultures. Stimulation index was determined as the ratio of mean triplicate value of IFNgamma induced by LPS stimulated DC compared to control iDC. R2 is Pearson's correlation coefficient.
###end p 37
###begin title 38
###xml 32 35 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Th1 defect is not correlated to HCV-RNA content in monocytes
###end title 38
###begin p 39
###xml 215 216 215 216 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 228 237 228 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002260-g003">figure 3A</xref>
###xml 420 429 420 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002260-g003">figure 3B</xref>
###xml 16 19 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 40 48 <span type="species:ncbi:9606">patients</span>
###xml 151 154 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 201 204 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 240 243 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 326 329 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 476 479 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 622 625 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
The presence of HCV-RNA in monocytes of patients has been previously described and was confirmed by our results. However, we found a very low level of HCV-RNA in these cells with less than 4 copies of HCV-RNA for 103 monocytes (figure 3A). HCV-RNA content in PBL was even lower. Moreover we did not observe any correlation of HCV-RNA content in blood monocytes with the intensity of the Th1 defect upon LPS stimulation (figure 3B). After differentiation of monocytes into DC, HCV-RNA level was extremely low and at the limit of the detection threshold (data not shown). Therefore, it is very unlikely that the presence of HCV-RNA in monocytes or in DC could be responsible for the Th1 defect.
###end p 39
###begin title 40
###xml 0 3 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 77 80 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 81 89 <span type="species:ncbi:9606">patients</span>
HCV-RNA content in monocytes does not correlate with Th1 defect of MoDC from HCV patients.
###end title 40
###begin p 41
###xml 80 81 80 81 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 525 534 521 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002260-g001">figure 1A</xref>
###xml 651 652 647 648 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 55 58 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 116 119 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 141 149 <span type="species:ncbi:9606">patients</span>
###xml 251 254 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 340 347 <span type="species:ncbi:9606">patient</span>
###xml 536 539 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
(A) Quantification by RT-PCR of the positive strand of HCV-RNA extracted from 106 monocytes or PBL from 11 distinct HCV chronically infected patients. RNA extraction was realized in triplicate and the mean value of three quantifications is shown. (B) HCV-RNA content in monocytes was plotted against the stimulation index obtained for each patient. Stimulation index was calculated as the ratio of IFNgamma secretion by T cells induced by LPS-treated DC compared to iDC in allogeneic MLR experiments realized as described in figure 1A. HCV-RNA in monocytes and the stimulation index are not linearly correlated with a Pearson correlation coefficient R2 close to zero.
###end p 41
###begin title 42
Th1 function can be restored by inhibition of the MEK-ERK pathway
###end title 42
###begin p 43
###xml 255 259 255 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002260-Ardeshna1">[30]</xref>
###xml 260 264 260 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002260-Agaugue1">[34]</xref>
###xml 394 398 394 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002260-Agaugue2">[35]</xref>
###xml 908 917 900 909 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002260-g004">figure 4A</xref>
###xml 1126 1135 1114 1123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002260-g004">figure 4B</xref>
###xml 102 105 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 106 114 <span type="species:ncbi:9606">patients</span>
###xml 548 551 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 810 813 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 835 843 <span type="species:ncbi:9606">patients</span>
###xml 969 977 <span type="species:ncbi:9606">patients</span>
###xml 983 991 <span type="species:ncbi:9606">patients</span>
###xml 1180 1183 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1184 1192 <span type="species:ncbi:9606">patients</span>
Since DC differentiation occur in absence of viral components, monocytes may have been conditioned in HCV patients by signals affecting their differentiation into mature DC. p38-MAPK and ERK kinases have been shown to play a role in TLR4 maturation of DC [30]-[34]. We previously found that the hyperactivation of ERK pathway could disable the Th1 function of DC treated by 1-methyl-tryptophan [35]. Therefore the MEK inhibitor PD98059 (PD) that prevents ERK phosphorylation was used to analyze the involvement of this pathway in the Th1 defect of HCV MoDC. These cells were treated at day 4 with PD before LPS stimulation at day 5. DC harvested at day 6 were washed and co-cultured with allogeneic T cells and IFNgamma secretion was quantified. The results show that blocking the MEK-ERK pathway in MoDC from HCV chronically-infected patients restored their ability to induce IFNgamma secretion by T cells (figure 4A). The restoration has been observed for 6 out of 7 patients. For patients DC that responded to ERK inhibitor treatment, the stimulation index for IFNgamma secretion was increased by more than 5 fold in mean (figure 4B). These results suggest that monocytes from HCV patients display an altered ERK pathway that can interfere with LPS-induced maturation.
###end p 43
###begin title 44
###xml 78 81 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 82 90 <span type="species:ncbi:9606">patients</span>
ERK inhibition can restore the Th1 function of MoDC from chronically-infected HCV patients stimulated by LPS.
###end title 44
###begin p 45
###xml 33 36 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 58 66 <span type="species:ncbi:9606">patients</span>
###xml 382 385 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 386 393 <span type="species:ncbi:9606">patient</span>
###xml 667 670 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 671 679 <span type="species:ncbi:9606">patients</span>
MoDC from healthy individuals or HCV chronically infected patients were treated at day 5 with LPS, 24h after addition of the ERK pathway inhibitor PD. DC harvested at day 6 were cocultured for 5 days with allogeneic T cells at a ratio of 1/10 DC/T cell. IFNgamma was measured by CBA in supernatants of cocultures. (A) Comparison of MoDC from one healthy donor (filled bars) and one HCV patient (opened bars) in a MLR using the same allogeneic T cells. IFNgamma secretion was normalized to 100% for control healthy LPS-treated MoDC. Mean+/-SD of three independent experiments in triplicates. (B) Treatment with the ERK inhibitor PD of MoDC from 7 chronically-infected HCV patients before LPS stimulation. Stimulation index was determined as the ratio of mean triplicate value of IFNgamma induced by LPS-stimulated DC compared to control iDC. Statistical analysis was performed using the Student's test for paired data.
###end p 45
###begin title 46
###xml 15 18 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 19 27 <span type="species:ncbi:9606">patients</span>
Monocytes from HCV patients secrete higher amounts of cytokines and chemokines
###end title 46
###begin p 47
###xml 340 348 340 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002260-g005">figure 5</xref>
###xml 735 743 721 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002260-g006">figure 6</xref>
###xml 274 277 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 278 286 <span type="species:ncbi:9606">patients</span>
###xml 506 509 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 692 695 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 696 704 <span type="species:ncbi:9606">patients</span>
###xml 926 929 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 930 938 <span type="species:ncbi:9606">patients</span>
###xml 1036 1039 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
To analyze the activation state of monocytes, we measured their capacity to secrete cytokines and chemokines without stimulation or in response to a 24h-treatment with TLR ligands. We did not found any significant difference in the response to TLR ligands of monocytes from HCV patients compared to those isolated from healthy individuals (figure 5) as assessed by their similar levels of secretion of IL-6, IL-1beta, TNFalpha, IL-10, IP-10 and MIP-1alpha and beta. Especially no defect in the response of HCV-monocytes to TLR4 ligand could be detected. In contrast a difference was observed on non-stimulated monocytes as their basal level of cytokine and chemokine secretion was higher for HCV patients than for healthy individuals (figure 6). The difference is especially important for MIP-1 alpha and beta, IL-6 and IL-8. The global increase in all cytokines and chemokines measured, strongly suggests that monocytes from HCV patients have an elevated activation state probably resulting from environmental modifications induced by HCV infection. This increased level of cytokine secretion may interfere with DC differentiation resulting in a Th1 defect in their response to LPS.
###end p 47
###begin title 48
Cytokine and chemokine secretions of monocytes.
###end title 48
###begin p 49
###xml 29 32 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 54 62 <span type="species:ncbi:9606">patients</span>
###xml 425 428 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 429 437 <span type="species:ncbi:9606">patients</span>
Monocytes were isolated from HCV chronically-infected patients (A, C, E) or healthy individuals (B, D, F). They were incubated for 24h in the presence or not (control) of TLR ligands. Cytokines (A-D) and chemokines (E, F) were measured in the supernatants using CBA inflammation kit for IL-6, TNFalpha, IL-1beta and IL-10 and specific CBA Flex kits for IP-10, MIP-1alpha and MIP-1beta. Mean secretion+/-SD for five different HCV patients and healthy donors is shown.
###end p 49
###begin title 50
Cytokine or chemokine secretion by non-stimulated monocytes.
###end title 50
###begin p 51
###xml 29 32 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 54 62 <span type="species:ncbi:9606">patients</span>
###xml 308 311 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 312 320 <span type="species:ncbi:9606">patients</span>
Monocytes were isolated from HCV chronically-infected patients or healthy individuals. They were incubated for 24h in culture medium. Cytokines and chemokines were measured in the supernatants using CBA inflammation kit and specific CBA Flex kits respectively. Individual secretion values for five different HCV patients and healthy donors are shown by circles and the mean secretion is marked by the line. Statistical analysis was performed using the Student's test.
###end p 51
###begin title 52
MIP-1beta interferes with monocyte differentiation into DC, leading to Th1 disabled DC
###end title 52
###begin p 53
###xml 462 470 442 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002260-g007">figure 7</xref>
MIP-1alpha and beta can both stimulate CCR5, resulting in ERK activation. We analyzed the impact of MIP-1 beta that can be secreted by monocytes on DC differentiation. Monocytes from healthy individuals were differentiated in DC with GM-CSF and IL-4 in the presence of 200 ng/ml MIP-1beta. DC collected at day 6, after 24 h maturation with LPS, presented a reduced ability to induce IFNgamma secretion by T cells compared to DC differentiated without MIP-1beta (figure 7). This Th1 deficient function of DC could be partially restored by pre-treatment with the MEK inhibitor 24 h prior to LPS maturation. A similar tendency was observed for MIP-1alpha although data were not statistically significative (data not shown). These results show that introduction of MIP-1 at early stage of differentiation of MoDC results in DC with reduced Th1 function in response to LPS stimulation, a mechanism involving the MEK/ERK pathway.
###end p 53
###begin title 54
MIP-1beta interfere with monocyte differentiation into DC.
###end title 54
###begin p 55
Monocytes isolated from an healthy individual were differentiated into DC in presence or not of 200 ng/ml MIP-1beta. When indicated, monocytes were treated with the MEK inhibitor (PD) at day 4 and maturation was induced by LPS at day 5. Cells harvested at day 6, were cocultured for 5 days with allogeneic T cells at a ratio of 1/10 DC/T cell in triplicates. IFNgamma was measured by CBA in supernatant of cocultures. Mean IFNgamma secretion+/-SD of triplicate wells is shown. * The mean IFNgamma secretion stimulated by Mo-DC treated with MIP-1beta and LPS is significantly reduced compared to that of MoDC treated with LPS with p<0.05 in a Student's test.
###end p 55
###begin title 56
Discussion
###end title 56
###begin p 57
###xml 678 682 674 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002260-Deforges1">[36]</xref>
###xml 684 688 680 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002260-Diaz1">[37]</xref>
###xml 1256 1260 1252 1256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002260-Abreu1">[38]</xref>
###xml 42 45 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 67 75 <span type="species:ncbi:9606">patients</span>
###xml 630 633 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
In this paper, we observed that MoDC from HCV chronically infected patients presented a defective ability to stimulate IFNgamma secretion by T cells upon LPS maturation. The allostimulatory defect was observed only when DC were stimulated with the TLR4 ligand LPS and not with TLR3, TLR2/6 or TLR1/2 ligands. A growing list of molecules from bacteria, viruses, and parasites can interfere with TLR4 signaling. This underlines the crucial role of TLR4 pathway in the innate recognition of pathogens but may also reveal microbial strategies evolved to facilitate infection. Physiological relevance of TLR4 signaling interference by HCV may relate to liver and intestine infection [36], [37]. The liver lies directly downstream of the gut and is therefore constantly exposed to antigens and microbial products derived from the intestine. The control of liver inflammation and tolerance to gut-derived antigens (food antigens and commensal bacteria) is likely to rely, at least in part, on functional characteristics of hepatic and intestinal antigen presenting cells. One of these characteristics is the modulation of TLR4 signaling under the dual pressure of protecting the host from pathogenic infections and coexistence with the myriad commensal organisms [38].
###end p 57
###begin p 58
###xml 247 251 247 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002260-Andre1">[27]</xref>
###xml 253 257 253 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002260-Diaz1">[37]</xref>
###xml 259 263 259 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002260-Andre2">[39]</xref>
###xml 264 268 264 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002260-Diaz2">[41]</xref>
###xml 624 628 624 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002260-Diaz1">[37]</xref>
###xml 949 953 949 953 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002260-Agaugue1">[34]</xref>
###xml 1471 1475 1471 1475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002260-Zhao1">[42]</xref>
###xml 1630 1634 1630 1634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002260-Lupo1">[43]</xref>
###xml 1635 1639 1635 1639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002260-Walton2">[46]</xref>
###xml 1788 1792 1788 1792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002260-Napolitano1">[47]</xref>
###xml 2063 2067 2063 2067 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002260-Zeyda1">[48]</xref>
###xml 2293 2297 2285 2289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002260-Coutant1">[49]</xref>
###xml 30 33 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 142 145 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 197 205 <span type="species:ncbi:9606">patients</span>
###xml 456 464 <span type="species:ncbi:9606">patients</span>
###xml 974 977 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 978 986 <span type="species:ncbi:9606">patients</span>
###xml 1340 1343 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1406 1411 <span type="species:ncbi:9606">human</span>
###xml 1691 1694 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1695 1703 <span type="species:ncbi:9606">patients</span>
###xml 1753 1758 <span type="species:ncbi:9606">human</span>
There are several reasons for HCV to interfere preferentially with the TLR4 pathway. This could first reflect the action of LVP on monocytes. HCV can circulate in the blood of chronically infected patients in the form of Lipo-Viro-Particles (LVP) [27], [37], [39]-[41]. These particles are triglyceride-rich lipoproteins, containing viral RNA and capsids and carrying the viral envelope proteins at their surface. LVP are found in all chronically infected patients and can represent a variable proportion of the total viral load ranging from a few percent to 90 percent. They originate from both the liver and the intestine [37]. We previously reported that LVP can interfere with TLR4-triggered maturation of DC, resulting in cells having a better potential to stimulate a Th2 response rather than a Th1 response of T cells. This shift of DC function did not occur upon pIC stimulation and was found to be dependent on ERK and p-38-MAPK activation [34]. Although MoDC from HCV patients did not acquire a Th2 function, one intriguing possibility is that LVP could interact with blood monocytes and modify their capacities to differentiate into DC. The impact of LVP on blood monocytes remains to be analyzed but it could be mediated either by the viral material carried by the particle or by its lipid contain. It was previously shown that HCV E2 envelope protein can induce ERK and p-38-MAPK signaling in human T cells via both CD81 and Low-Density Lipoprotein Receptor [42]. LVP could also contain modified lipids that could activate ERK or alter lipid raft distribution, thus inhibiting subsequent LPS maturation of DC ex vivo [43]-[46]. It has been shown recently that lipoproteins from HCV patients induced some modifications of lipid synthesis in human monocyte-derived macrophages [47]. LVP could thus interfere with TLR4 signaling by modifying the lipid composition of the plasma membrane of monocytes. Among other possibilities, the induction of Th1 responses can be inhibited by polyunsaturated fatty acids (PUFA), possibly by insertion in the membrane [48]. PUFA are known to be agonists of PPARgamma and we have previously shown that activating PPARgamma in DC can inhibit their functional maturation, leading to phenotypically mature DC unable to induce a Th1 response of T cells [49].
###end p 58
###begin p 59
###xml 555 559 551 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002260-Rui1">[50]</xref>
###xml 752 756 748 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002260-Agaugue2">[35]</xref>
###xml 1496 1500 1488 1492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002260-Rui1">[50]</xref>
###xml 13 16 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 17 25 <span type="species:ncbi:9606">patients</span>
###xml 974 977 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 978 986 <span type="species:ncbi:9606">patients</span>
###xml 1080 1088 <span type="species:ncbi:9606">patients</span>
In MoDC from HCV patients, TLR4 signaling remains functional since the ability of DC to induce IFNgamma secretion by T cells can be restored by treatment with the MEK inhibitor 24 h prior to LPS maturation. The RAS/MEK/ERK pathway is involved in the regulation of differentiation in many cell types. However, the function of this pathway depends on the cell type, the differentiation stage of the cell and the type of stimulation of the receptor. Interestingly, ERK phosphorylation is involved in the inhibition of the B cell response to TLR4 agonist LPS [50]. We previously observed that an increased phosphorylation of p38 and ERK MAP-kinases and a sustained activation of the transcription factor c-Fos were correlated to a Th2 shift of DC function [35]. In this model of functional shift induced by 1-methyl-tryptophan, we found that ERK inhibition could restore the ability of DC to stimulate IFNgamma secretion by T cells. This was also the case for DC generated from HCV patients as shown here. This result strongly suggests that monocytes isolated from the blood of these patients present some modifications resulting in a deregulation of ERK phosphorylation. This dysfunction can be due either to a positive stimulation of the MEK/ERK pathway or to the absence of negative regulation by phosphatases such as the dual-specific phosphatases (DUSP) that oppose the action of MEK by dephosphorylating ERK. This latter mechanism has been observed for TLR4-induced plasma cell differentiation [50].
###end p 59
###begin p 60
###xml 267 268 267 268 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 105 108 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 109 117 <span type="species:ncbi:9606">patients</span>
###xml 166 169 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 376 379 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 460 463 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 537 540 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 607 610 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 794 797 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 807 815 <span type="species:ncbi:9606">patients</span>
The deficient response to LPS stimulation of MoDC points at an alteration of the monocytes isolated from HCV patients. This defect is not correlated to the amount of HCV-RNA detected in monocytes. The low content of viral RNA in these cells (less than 4 copies for 103 cells) is in favor of a role of environmental factors affecting monocytes function. No or trace amounts of HCV-RNA remained in differentiated DC indicating that they probably did not present HCV peptides. In consequence, these cells should not specifically display an HCV-specific defect in term of antigen presentation and activation of HCV-specific T cells. We also found that the addition of IFNalpha 24h prior induction of maturation by LPS slightly improved the ability of DC differentiated from monocytes of 4 out of 6 HCV infected patients, to stimulate IFNgamma secretion by T cells (data not shown). This weak restoration of the TLR4 stimulation efficiency is thus independent of the antiviral effect of IFNalpha and probably relate to signaling events triggered by IFNalpha.
###end p 60
###begin p 61
###xml 825 834 815 824 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002260.s002">Figure S2</xref>
###xml 930 934 913 917 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002260-Lichterfeld1">[51]</xref>
###xml 1169 1173 1152 1156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002260-Tomkowicz1">[52]</xref>
###xml 15 18 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 19 27 <span type="species:ncbi:9606">patients</span>
###xml 258 261 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 262 270 <span type="species:ncbi:9606">patients</span>
###xml 353 356 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 592 595 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 596 604 <span type="species:ncbi:9606">patients</span>
###xml 740 743 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 744 752 <span type="species:ncbi:9606">patients</span>
###xml 917 920 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 921 929 <span type="species:ncbi:9606">patients</span>
###xml 1151 1156 <span type="species:ncbi:9606">human</span>
###xml 1204 1207 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Monocytes from HCV patients can respond to LPS stimulation, secreting cytokines and chemokines with an efficiency similar to that of control monocytes. Desensitization of these cells to LPS can therefore be excluded. However, we observed that monocytes from HCV patients had an elevated basal activation state compared to monocytes from healthy donors. HCV-monocytes secreted higher levels of cytokines and chemokines among which, MIP-1 alpha and beta. DC differentiated from healthy monocytes in the presence of MIP-1beta, displayed a similar Th1 defect after LPS stimulation than MoDC from HCV patients. This defect could be overcome by inhibition of the ERK pathway. Addition of anti-MIP-1 antibodies during differentiation of MoDC from HCV patients tend to restore the ability of these cells to stimulate a Th1 response (Figure S2). The MIP-1 alpha and beta chemokines are found in higher amounts in the blood of HCV patients [51] and can both stimulate the CCR5 receptor. Although the mechanism involving the ERK pathway remains to be determined, ERK hyperactivation could result from CCR5 stimulation by MIP-1 as it was previously described for human macrophages [52]. Increased MIP-1 secretion by HCV monocytes may thus interfere with DC differentiation in vivo.
###end p 61
###begin p 62
###xml 152 155 152 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002260-Kanto3">[8]</xref>
###xml 157 161 157 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002260-RodrigueGervais1">[16]</xref>
###xml 163 167 163 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002260-Averill1">[53]</xref>
###xml 314 318 314 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002260-Waggoner1">[54]</xref>
###xml 807 811 807 811 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002260-RodrigueGervais1">[16]</xref>
###xml 907 910 907 910 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002260-Kanto1">[6]</xref>
###xml 912 916 912 916 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002260-RodrigueGervais1">[16]</xref>
###xml 222 225 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 345 348 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 349 357 <span type="species:ncbi:9606">patients</span>
###xml 624 627 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 628 636 <span type="species:ncbi:9606">patients</span>
###xml 886 889 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 890 898 <span type="species:ncbi:9606">patients</span>
Several recent papers also described Th1 deficient functions of circulating myeloid DC in specific conditions depending on the activation pathway of DC [8], [16], [53]. Recently, it has been shown that the core protein of HCV can inhibit the Th1 function of monocytes-derived DC via interaction with gC1q receptor [54]. LPS-stimulated MoDC from HCV patients showed a mature phenotype but a significant decrease of IL-12 secretion that could participate to the Th1 defect since the intensity of the Th1 defect was correlated to the intensity of IL-12 decrease. This selective defect of MoDC derived from chronically-infected HCV patients is in agreement with the absence of immunodeficiency and is in line with the study by Rodrigue-Gervais et al. showing deficient response to LPS of circulating DC ex-vivo [16]. A deficient secretion of IL-12 was also reported for circulating DC from HCV patients ex-vivo [6], [16].
###end p 62
###begin p 63
###xml 27 30 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
By acting on TLR4 pathway, HCV may thus exploit a natural protective mechanism of the liver and the intestine normally used to control inflammation and immunity to commensal microorganisms.
###end p 63
###begin title 64
Supporting Information
###end title 64
###begin p 65
(2.54 MB TIF)
###end p 65
###begin p 66
Click here for additional data file.
###end p 66
###begin p 67
(2.18 MB TIF)
###end p 67
###begin p 68
Click here for additional data file.
###end p 68
###begin p 69
###xml 266 269 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 270 278 <span type="species:ncbi:9606">patients</span>
Pr Stanislas Pol (Service d'hepatologie, Hopital Cochin, Paris), Dr Francoise Audat and Dr Francois Lefrere (departement de Biotherapie, Unite de Medecine transfusionnelle et d'hemapherese therapeutique, Necker Hospital) are gratefully acknowledged for selection of HCV patients and collection of blood samples. We thank Martine Carreras for her precious help in the experiments for supplementary figures. We thank F. Archer and K. Gallay for the management of the Level 3 security laboratory from IFR128 BioSciences Lyon-Gerland.
###end p 69
###begin title 70
References
###end title 70
###begin article-title 71
###xml 53 58 <span type="species:ncbi:12440">non-A</span>
Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome.
###end article-title 71
###begin article-title 72
###xml 0 17 <span type="species:ncbi:11103">Hepatitis C virus</span>
Hepatitis C virus shares amino acid sequence similarity with pestiviruses and flaviviruses as well as members of two plant virus supergroups.
###end article-title 72
###begin article-title 73
###xml 0 11 <span type="species:ncbi:11103">Hepatitis C</span>
Hepatitis C: the clinical spectrum of disease.
###end article-title 73
###begin article-title 74
###xml 38 46 <span type="species:ncbi:9606">patients</span>
###xml 79 96 <span type="species:ncbi:11103">hepatitis C virus</span>
Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection.
###end article-title 74
###begin article-title 75
###xml 64 75 <span type="species:ncbi:11103">hepatitis C</span>
Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection.
###end article-title 75
###begin article-title 76
###xml 85 102 <span type="species:ncbi:11103">hepatitis C virus</span>
Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals.
###end article-title 76
###begin article-title 77
###xml 119 136 <span type="species:ncbi:11103">hepatitis C virus</span>
Reduced numbers and impaired ability of myeloid and plasmacytoid dendritic cells to polarize T helper cells in chronic hepatitis C virus infection.
###end article-title 77
###begin article-title 78
###xml 52 60 <span type="species:ncbi:9606">patients</span>
###xml 75 92 <span type="species:ncbi:11103">hepatitis C virus</span>
Impaired function of dendritic cells circulating in patients infected with hepatitis C virus who have persistently normal alanine aminotransferase levels.
###end article-title 78
###begin article-title 79
###xml 99 107 <span type="species:ncbi:9606">patients</span>
###xml 121 132 <span type="species:ncbi:11103">hepatitis C</span>
Decreased interferon-alpha production and impaired T helper 1 polarization by dendritic cells from patients with chronic hepatitis C.
###end article-title 79
###begin article-title 80
###xml 92 109 <span type="species:ncbi:11103">hepatitis C virus</span>
Infection and dysfunction of circulating blood dendritic cells and their subsets in chronic hepatitis C virus infection.
###end article-title 80
###begin article-title 81
###xml 70 87 <span type="species:ncbi:11103">hepatitis C virus</span>
###xml 89 92 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 111 114 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 128 136 <span type="species:ncbi:9606">patients</span>
###xml 150 161 <span type="species:ncbi:11103">hepatitis C</span>
Isolation and functional analysis of circulating dendritic cells from hepatitis C virus (HCV) RNA-positive and HCV RNA-negative patients with chronic hepatitis C: role of antiviral therapy.
###end article-title 81
###begin article-title 82
###xml 42 50 <span type="species:ncbi:9606">patients</span>
###xml 77 94 <span type="species:ncbi:11103">hepatitis C virus</span>
Presence of functional dendritic cells in patients chronically infected with hepatitis C virus.
###end article-title 82
###begin article-title 83
###xml 86 94 <span type="species:ncbi:9606">patients</span>
###xml 108 119 <span type="species:ncbi:11103">hepatitis C</span>
Normal functional capacity in circulating myeloid and plasmacytoid dendritic cells in patients with chronic hepatitis C.
###end article-title 83
###begin article-title 84
###xml 85 96 <span type="species:ncbi:11103">hepatitis C</span>
###xml 97 105 <span type="species:ncbi:9606">patients</span>
Comparable functions of plasmacytoid and monocyte-derived dendritic cells in chronic hepatitis C patients and healthy donors.
###end article-title 84
###begin article-title 85
###xml 68 85 <span type="species:ncbi:11103">hepatitis C virus</span>
###xml 124 132 <span type="species:ncbi:9606">patients</span>
###xml 138 155 <span type="species:ncbi:11103">hepatitis C virus</span>
Decrease and dysfunction of dendritic cells correlate with impaired hepatitis C virus-specific CD4+ T-cell proliferation in patients with hepatitis C virus infection.
###end article-title 85
###begin article-title 86
###xml 73 78 <span type="species:ncbi:9606">human</span>
###xml 127 144 <span type="species:ncbi:11103">hepatitis C virus</span>
###xml 154 162 <span type="species:ncbi:9606">patients</span>
Poly(I:C) and lipopolysaccharide innate sensing functions of circulating human myeloid dendritic cells are affected in vivo in hepatitis C virus-infected patients.
###end article-title 86
###begin article-title 87
###xml 18 35 <span type="species:ncbi:11103">hepatitis C virus</span>
Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF.
###end article-title 87
###begin article-title 88
###xml 35 48 <span type="species:ncbi:11234">measles virus</span>
Hemagglutinin protein of wild-type measles virus activates toll-like receptor 2 signaling.
###end article-title 88
###begin article-title 89
###xml 0 21 <span type="species:ncbi:10359">Human cytomegalovirus</span>
Human cytomegalovirus activates inflammatory cytokine responses via CD14 and Toll-like receptor 2.
###end article-title 89
###begin article-title 90
Dual recognition of herpes simplex viruses by TLR2 and TLR9 in dendritic cells.
###end article-title 90
###begin article-title 91
###xml 64 91 <span type="species:ncbi:12814">respiratory syncytial virus</span>
Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus.
###end article-title 91
###begin article-title 92
###xml 0 6 <span type="species:ncbi:10090">Murine</span>
Murine retroviruses activate B cells via interaction with toll-like receptor 4.
###end article-title 92
###begin article-title 93
###xml 58 85 <span type="species:ncbi:12814">respiratory syncytial virus</span>
Involvement of toll-like receptor 4 in innate immunity to respiratory syncytial virus.
###end article-title 93
###begin article-title 94
Subversion of the innate immune system by a retrovirus.
###end article-title 94
###begin article-title 95
###xml 0 17 <span type="species:ncbi:11103">Hepatitis C virus</span>
Hepatitis C virus nonstructural protein 5A modulates the toll-like receptor-MyD88-dependent signaling pathway in macrophage cell lines.
###end article-title 95
###begin article-title 96
Oxidized low-density lipoprotein promotes mature dendritic cell transition from differentiating monocyte.
###end article-title 96
###begin article-title 97
###xml 46 63 <span type="species:ncbi:11103">hepatitis C virus</span>
Characterization of low- and very-low-density hepatitis C virus RNA- containing particles.
###end article-title 97
###begin article-title 98
###xml 16 19 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Quantitation of HCV RNA using real-time PCR and fluorimetry.
###end article-title 98
###begin article-title 99
###xml 40 57 <span type="species:ncbi:11103">hepatitis C virus</span>
Automated quantitative determination of hepatitis C virus viremia by reverse transcription-PCR.
###end article-title 99
###begin article-title 100
###xml 152 157 <span type="species:ncbi:9606">human</span>
The PI3 kinase, p38 SAP kinase, and NF-kappaB signal transduction pathways are involved in the survival and maturation of lipopolysaccharide-stimulated human monocyte-derived dendritic cells.
###end article-title 100
###begin article-title 101
###xml 146 151 <span type="species:ncbi:9606">human</span>
Extracellular signal-regulated protein kinase signaling pathway negatively regulates the phenotypic and functional maturation of monocyte-derived human dendritic cells.
###end article-title 101
###begin article-title 102
###xml 78 83 <span type="species:ncbi:9606">human</span>
A critical role for p38 mitogen-activated protein kinase in the maturation of human blood-derived dendritic cells induced by lipopolysaccharide, TNF-alpha, and contact sensitizers.
###end article-title 102
###begin article-title 103
Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos.
###end article-title 103
###begin article-title 104
###xml 0 11 <span type="species:ncbi:11103">Hepatitis C</span>
###xml 57 65 <span type="species:ncbi:9606">Patients</span>
Hepatitis C Lipo-Viro-Particle from Chronically Infected Patients Interferes with TLR4 Signaling in Dendritic Cell.
###end article-title 104
###begin article-title 105
1-Methyl-tryptophan can interfere with TLR signaling in dendritic cells independently of IDO activity.
###end article-title 105
###begin article-title 106
###xml 14 31 <span type="species:ncbi:11103">hepatitis C virus</span>
Expression of hepatitis C virus proteins in epithelial intestinal cells in vivo.
###end article-title 106
###begin article-title 107
###xml 28 45 <span type="species:ncbi:11103">Hepatitis C virus</span>
Preferential association of Hepatitis C virus with apolipoprotein B48-containing lipoproteins.
###end article-title 107
###begin article-title 108
TLR signaling in the gut in health and disease.
###end article-title 108
###begin article-title 109
###xml 0 17 <span type="species:ncbi:11103">Hepatitis C virus</span>
Hepatitis C virus particles and lipoprotein metabolism.
###end article-title 109
###begin article-title 110
###xml 20 37 <span type="species:ncbi:11103">hepatitis C virus</span>
Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients.
###end article-title 110
###begin article-title 111
###xml 28 39 <span type="species:ncbi:11103">hepatitis C</span>
Transmission of low-density hepatitis C viral particles during sexually transmitted acute resolving infection.
###end article-title 111
###begin article-title 112
###xml 56 73 <span type="species:ncbi:11103">hepatitis C virus</span>
###xml 97 102 <span type="species:ncbi:9606">human</span>
Up-regulation of ERK and p38 MAPK signaling pathways by hepatitis C virus E2 envelope protein in human T lymphoma cell line.
###end article-title 112
###begin article-title 113
Activation of phospholipase A(2) and MAP kinases by oxidized low-density lipoproteins in immortalized GP8.39 endothelial cells.
###end article-title 113
###begin article-title 114
Activation of MAPK by modified low-density lipoproteins in vascular smooth muscle cells.
###end article-title 114
###begin article-title 115
Specific phospholipid oxidation products inhibit ligand activation of toll-like receptors 4 and 2.
###end article-title 115
###begin article-title 116
A role for neutral sphingomyelinase activation in the inhibition of LPS action by phospholipid oxidation products.
###end article-title 116
###begin article-title 117
###xml 71 79 <span type="species:ncbi:9606">patients</span>
###xml 85 96 <span type="species:ncbi:11103">hepatitis C</span>
Very low density lipoprotein and low density lipoprotein isolated from patients with hepatitis C infection induce altered cellular lipid metabolism.
###end article-title 117
###begin article-title 118
Polyunsaturated fatty acids block dendritic cell activation and function independently of NF-kappaB activation.
###end article-title 118
###begin article-title 119
Sensing environmental lipids by dendritic cell modulates its function.
###end article-title 119
###begin article-title 120
ERK signaling is a molecular switch integrating opposing inputs from B cell receptor and T cell cytokines to control TLR4-driven plasma cell differentiation.
###end article-title 120
###begin article-title 121
###xml 105 113 <span type="species:ncbi:9606">patients</span>
###xml 127 138 <span type="species:ncbi:11103">hepatitis C</span>
Reduced CC chemokine receptor (CCR) 1 and CCR5 surface expression on peripheral blood T lymphocytes from patients with chronic hepatitis C infection.
###end article-title 121
###begin article-title 122
###xml 82 87 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 97 102 <span type="species:ncbi:9606">human</span>
The Src kinase Lyn is required for CCR5 signaling in response to MIP-1beta and R5 HIV-1 gp120 in human macrophages.
###end article-title 122
###begin article-title 123
###xml 66 69 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Differential dysfunction in dendritic cell subsets during chronic HCV infection.
###end article-title 123
###begin article-title 124
###xml 0 3 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
HCV core protein interaction with gC1q receptor inhibits Th1 differentiation of CD4+ T cells via suppression of dendritic cell IL-12 production.
###end article-title 124
###begin p 125
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 125
###begin p 126
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported by the Agence Nationale de la Recherche sur le Sida et les hepatites (ANRS), Institut National de la Sante et de la Recherche Medicale (Inserm) and les Hospices Civils de Lyon (HCL). S.A was recipient of a doctoral scholarship from the Association pour la Recherche sur le Cancer.
###end p 126

